25 Stocks Moving In Thursday's Pre-Market Session

Gainers

• Electro Scientific Industries, Inc. ESIO rose 27.2 percent to $20.74 as the company reported upbeat Q2 results and issued a strong Q3 forecast.
• Neurocrine Biosciences, Inc. NBIX rose 24.3 percent to $75.75 in pre-market trading after the company reported strong results for its third quarter.
• TransAct Technologies Incorporated TACT rose 12.2 percent to $11.00in the pre-market trading session on better-than-expected Q3 results.
• China Internet Nationwide Fncl Srvcs Inc CIFS shares rose 9.8 percent to $33.15 in the pre-market trading session after dropping 27.05 percent on Wednesday.
• Attunity Ltd ATTU shares rose 8.5 percent to $7.13 in the pre-market trading session after the company reported Q3 results and named Mark Logan as Chief Operating Officer.
• Dicerna Pharmaceuticals Inc DRNA shares rose 8.2 percent to $6.10 in pre-market trading. Boehringer Ingelheim and Dicerna reported a research collaboration to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis.
• Tenaris SA (ADR) TS rose 7.1 percent to $29.30 in pre-market trading. Tenaris reported Q3 earnings of $0.09 per share on sales of $1.303 billion.
• L Brands Inc LB shares rose 6.5 percent to $46.44 in pre-market trading after reporting encouraging October sales data.
• Exelixis, Inc. EXEL rose 6.1 percent to $25.70 in pre-market trading. Exelixis reported Q3 adjusted earnings of $0.26 per share on revenue of $152.5 million.
• W&T Offshore, Inc. WTI rose 5.5 percent to $3.49 in pre-market trading after reporting Q3 results.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

• IMPINJ Inc PI shares fell 27.7 percent to $23.70 in pre-market trading after Q3 earnings. The company's Q4 guidance fell way below estimates.
• Insys Therapeutics Inc INSY shares fell 17.5 percent to $4.20 as the company reported a wider-than-expected quarterly loss.
• Oclaro Inc OCLR fell 17.5 percent to $6.61 in pre-market trading, despite a Q1 earnings beat.
• Community Health Systems CYH fell 15.3 percent to $4.61 in pre-market trading following larger-than-expected Q3 loss.
• OraSure Technologies, Inc. OSUR fell 13.3 percent to $16.50 in pre-market trading. OraSure posted Q3 earnings of $0.09 per share on revenue of $42.3 million.
• Wayfair Inc W shares fell 12.6 percent to $65.02 in pre-market trading after reporting downbeat Q3 results.
• Teva Pharmaceutical Industries Ltd (ADR) TEVA fell 11.6 percent to $12.40 in pre-market trading after the company reported downbeat results for its third quarter and lowered its 2017 guidance.
• Newell Brands Inc NWL fell 10.6 percent to $36.65 in pre-market trading as the company posted weaker-than-expected Q3 results and lowered its forecast.
• Intellia Therapeutics Inc NTLA fell 9.9 percent to $22.95 in the pre-market trading session. Intellia Therapeutics priced its 6.25 million share offering at $24.00 per share.
• FireEye Inc FEYE fell 8.9 percent to $14.91 in pre-market trading. FireEye reported a narrower-than-expected loss for its third quarter, but issued a weak guidance for the current quarter.
• GoPro Inc GPRO fell 8.7 percent to $9.74 in pre-market trading. GoPro reported better-than-expected earnings for its third quarter. However, the company issued a weak Q4 guidance, with EPS in the range of 37 cents-47 cents, well short of Wall Street's 56-cent estimate.
• Cellectis SA (ADR) CLLS shares fell 7.6 percent to $26.96 in pre-market trading after dropping 16.65 percent on Wednesday.
• Symantec Corporation SYMC fell 7.3 percent to $29.80 in pre-market trading after the company reported weak quarterly earnings and issued a lower guidance.
• Epizyme Inc EPZM fell 7.1 percent to $15.00 in pre-market trading. Epizyme posted a Q3 loss of $0.63 per share. RBC Capital downgraded Epizyme from Outperform to Sector Perform.
• Tesla Inc TSLA shares fell 5.6 percent to $303.00 in pre-market trading. Tesla reported a third-quarter loss of $2.92 per share. The electric carmaker delivered third-quarter sales of $2.98 billion, beating estimates by $680 million.